Shichang Miao
Amgen (United States)(US)
Publications by Year
Research Areas
Chemokine receptors and signaling, Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research, Cytokine Signaling Pathways and Interactions, Hormonal Regulation and Hypertension
Most-Cited Works
- → T0070907, a Selective Ligand for Peroxisome Proliferator-activated Receptor γ, Functions as an Antagonist of Biochemical and Cellular Activities(2002)319 cited
- → Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study(2016)147 cited
- → Rubrolides A-H, metabolites of the colonial tunicate Ritterella rubra(1991)126 cited
- → Identification of Glutamic Acid 78 as the Active Site Nucleophile in Bacillus subtilis Xylanase Using Electrospray Tandem Mass Spectrometry(1994)106 cited
- → Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3(2007)104 cited
- → Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial(2012)98 cited
- → Secondary metabolites of the aspen fungus Stachybotrys cylindrospora(1993)94 cited
- → Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.(2018)91 cited
- → CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease(2012)86 cited
- → C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study(2021)86 cited